Q-omics provides the consensus-scored CYCSP39 profile across patient tissues and cancer cell-line models. CYCSP39 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, CYCSP39 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, CYCSP39 RNA expression shows 5,323 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, LUSC, and STAD as cancer lineages where CYCSP39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP39 survival associations across molecular data types. CYCSP39 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP39 RNA expression–survival associations across cancer types. High CYCSP39 expression shows unfavorable associations in THYM, CHOL, ESCA, LGG and LUAD, but favorable associations in ACC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for CYCSP39 RNA expression.
This table summarizes CYCSP39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP39 shows lower tumor expression in THCA and higher tumor expression in LUSC and LIHC. The LUSC box plot shows higher CYCSP39 RNA expression in tumor versus normal tissue (log2 FC = +0.113, t-test p = .002).
This table shows molecular features associated with CYCSP39 in patient tissues and cancer cell lines. In patient samples, CYCSP39 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
